Abdi İbrahim to start $115 million manufacturing investment early to drive Turkish economy
Turkish drugmaker Abdi İbrahim is to press ahead with two major manufacturing projects at its Istanbul site this year because it sees it as crucial to be ‘bolder in investment’ for the sake of the country’s future.
The combined $115 million investments in two facilities to manufacture sterile injectable products and oncological treatments were planned for 2017, the company having broken ground on Turkey's largest biotechnological pharmaceutical manufacturing facility at a cost of $100 million last year.
That has now been brought forward, Abdi İbrahim’s chairman Nezih Barut said, because the company had decided to share its enthusiasm with the industry and to “make an ambitious contribution to the construction of a robust economy.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze